公开(公告)号：JP2012139224A

公开(公告)日：2012-07-26

申请号：JP2012032142

申请日：2012-02-16

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: C12N15/02 ,  C12N15/09 ,  A61K31/436 ,  A61K31/519 ,  A61K31/573 ,  A61K31/706 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/00 ,  A61P3/08 ,  A61P3/10 ,  A61P5/14 ,  A61P5/16 ,  A61P5/40 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P15/08 ,  A61P15/10 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  A61P43/00 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C40B40/10

CPC classification number: C07K16/244 ,  A61K31/519 ,  A61K31/56 ,  A61K38/13 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  A61K39/395 ,  A61K31/00

Abstract: PROBLEM TO BE SOLVED: To provide a perfect human antibody IL-18 as a preferred IL-18 inhibitor, because parts of a chimera and humanized antibodies still remain as a murine sequence, and therefore, may cause an undesirable immune reaction if they are administered over a long period.SOLUTION: The present invention includes an antigen binding to a human interleukin-18, particularly an antigen binding to an epitope of a human IL-18. The antibody can be, for example, an entirely human antibody, a recombinant antibody, or monoclonal antibody. A preferred antibody has the high affinity for the hIL-18, and/or neutralizes an hIL-18 activity in vitro and in vivo. The antibody can be of a full-length or an antigen binding portion thereof. The methods of making and using the antibody are also provided. The antibody, or the antibody portion is useful for detecting the hIL-18, and also useful, for example, for inhibiting a hIL-18 activity in a human subject suffering from a disorder in which the hIL-18 is detrimental.

Abstract translation: 要解决的问题：提供完美的人抗体IL-18作为优选的IL-18抑制剂，因为嵌合体和人源化抗体的一部分仍然保持为鼠序列，因此如果 它们长期施用。 解决方案：本发明包括与人白介素-18结合的抗原，特别是与人IL-18的表位结合的抗原。 抗体可以是例如完全人抗体，重组抗体或单克隆抗体。 优选的抗体对hIL-18具有高亲和力，和/或在体外和体内中和hIL-18活性。 抗体可以是全长或其抗原结合部分。 还提供了制备和使用抗体的方法。 抗体或抗体部分可用于检测hIL-18，并且还可用于例如在患有hIL-18有害的病症的人类受试者中抑制hIL-18活性。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：AR040603A1

公开(公告)日：2005-04-13

申请号：ARP030102605

申请日：2003-07-18

Applicant: ABBOTT LAB S A

Inventor： BANERJEE SUBHASHIS ,  TAYLOR LORI K ,  SPIEGLER CLIVE E ,  TRACEY DANIEL EDWARD ,  CHARTAS ELLIOT K ,  HOFFMAN REBECCA S ,  BARCHUK WILLIAM T ,  YAN PHILIP ,  MURTAZA ANWAR ,  SALFELD JOCHEN ,  FISCHKOFF STEVEN

IPC: A61K20060101 ,  A61K39/395 ,  C07K20060101 ,  C07K16/24 ,  A61P3/00 ,  A61P9/00 ,  A61P11/00 ,  A61P17/00 ,  A61P19/00 ,  A61P37/00

Abstract: El uso de un anticuerpo anti-TNF neutralizador, de gran afinidad en la elaboración de un medicamento para tratar un trastorno relacionado con TNF y un conjunto de elementos que comprende una composición farmacéutica que contiene dicho anticuerpo anti-TNF. Reivindicación 1: Un método de tratamiento de un trastorno relacionado con TNFalfa en un sujeto, donde trastorno relacionado con TNFalfa se selecciona del grupo formado por una espodiloartropía, un trastorno pulmonar, un trastorno coronario, un trastorno metabólico, anemia, dolor, un trastorno hepático, un trastorno de la piel, un trastorno de las unas o vasculitis, caracterizado porque comprende administrar al sujeto una cantidad eficaz para uso terapéutico de un anticuerpo anti-TNFalfa neutralizador, de gran afinidad, con lo cual se logra tratar dicho trastorno relacionado con TNFalfa. Reivindicación 15: Un conjunto de elementos, caracterizado porque comprende; a) una composición farmacéutica que comprende un anticuerpo anti-TNFalfa, o una porción que se une al antígeno del mismo, y un vehículo aceptable para uso farmacéutico; y b) instrucciones para la administración al sujeto de la composición farmacéutica con el anticuerpo anti-TNFalfa para tratar un sujeto que sufre de un trastorno relacionado con TNFalfa.

公开(公告)号：ZA200206266B

公开(公告)日：2003-11-06

申请号：ZA200206266

申请日：2002-08-06

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  C12N15/02 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C07K

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：AU2011201536A1

公开(公告)日：2011-04-28

申请号：AU2011201536

申请日：2011-04-05

Applicant: ABBOTT LAB

Inventor： DUNCAN ALEXANDER ROBERT ,  LABKOVSKY BORIS ,  SHORROCK CELIA ELIZABETH ,  SALFELD JOCHEN ,  MANKOVICH JOHN ,  ELIZABETH THOMPSON JULIA ,  WHITE MICHAEL ,  ROGUSKA MIKE ,  DIXON RICHARD W ,  BROCKLEHURST SIMON MARK ,  LENNARD SIMON NICHOLAS ,  GHAYUR TARIQ

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：HU0300423A2

公开(公告)日：2003-06-28

申请号：HU0300423

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： BROCKLEHURST SIMON MARK ,  DIXON RICHARD W ,  DUNCAN ALEXANDER ROBERT ,  GHAYUR TARIQ ,  LABKOVSKY BORIS ,  LENNARD SIMON NICHOLAS ,  MANKOVICH JOHN ,  ROGUSKA MIKE ,  SALFELD JOCHEN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  WHITE MICHAEL

IPC: A61K39/395 ,  C12N15/02 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：SK12942002A3

公开(公告)日：2003-05-02

申请号：SK12942002

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: A61K39/395 ,  C12N15/02 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  C07K16/00

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：CA2800450A1

公开(公告)日：2001-08-16

申请号：CA2800450

申请日：2001-02-09

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD W ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ROBERT ,  BROCKLEHURST SIMON MARK ,  MANKOVICH JOHN ,  SHORROCK CELIA PATRICIA ,  THOMPSON JULIA ELIZABETH ,  LENNARD SIMON NICHOLAS

IPC: C07K16/24 ,  C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K1/22 ,  C07K14/54 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/13 ,  C12P21/08 ,  C40B30/04

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

公开(公告)号：BG111004A

公开(公告)日：2011-11-30

申请号：BG11100411

申请日：2011-07-29

Applicant: ABBOTT LAB

Inventor： GHAYUR TARIQ ,  DIXON RICHARD ,  ROGUSKA MIKE ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  SALFELD JOCHEN ,  DUNCAN ALEXANDER ,  BROCKLEHURST SIMON ,  MANKOVICH JOHN ,  SHORROCK CELIA ,  THOMPSON JULIA ,  LENNARD SIMON

IPC: C07K16/24 ,  C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: Осигуренисаантитела, коитосесвързватс човешкиинтерлевкин-18 (hIL-18), по-специалноантитела, контосесвързватс епитопа(ите) начовешки IL-18. Антителатамогатдабъдатнапримеризцялочовешкиантитела, рекомбинантниантителаилимоноклоналниантитела. Предпочитанитеантителаиматвисокафинитеткъм hIL-18 инеутрализиратактивносттана hIL-18 in vitro и in vivo. Антитялоотизобретениетоможедабъдес пълнатадължинанаантитялоилиантиген-свързващанеговачаст. Осигуренисасъщометодзаполучаванеи методзаизползваненаантителаотизобретението. Антителатаиличастинаантителатаотизобретениетосеизползватзадетекцияна hIL-18 изаинхибираненаактивносттана hIL-18, напримерв обект-човек, койтострадаотнарушение, прикоетоактивносттана hIL-18 евредна.

公开(公告)号：AR080840A1

公开(公告)日：2012-05-09

申请号：ARP110101162

申请日：2011-04-07

Applicant: ABBOTT LAB

Inventor： SALFELD JOCHEN ,  GHAYUR TARIQ ,  GOODREAU CARRIE L ,  ISAKSON PETER C ,  BENATUIL LORENZO

IPC: C07K14/475 ,  A61K39/395 ,  A61P21/00 ,  A61P23/00 ,  A61P11/06 ,  C12N15/12 ,  C12N15/63 ,  C12N15/79 ,  C12N15/85 ,  G01N33/53

Abstract: Composiciones basadas en anticuerpos. Moléculas relacionadas. Composiciones farmacéuticas que comprenden dichos anticuerpos. Métodos terapéuticos y de diagnostico donde se emplean dichos anticuerpos. Se provee además un ácido nucleico que codifica la proteína de union humanizada, un vector que comprende dicho ácido nucleico, una célula huésped conteniendo el vector. Reivindicacion 1: Una proteína de union humanizada caracterizada porque comprende un dominio de union al antígeno que puede unirse al factor de necrosis tumoral-alfa humano (TNF-alfa), donde el dominio de union al antígeno comprende al menos un conjunto de CDR que comprende una secuencia de aminoácidos que abarca los residuos 31-35 de SEQ ID N°: 22, los residuos 50- 65 de SEQ ID N°: 22, los residuos 98-106 de SEQ ID N°: 22, los residuos 24-34 de SEQ ID N°: 23, los residuos 50-56 de SEQ ID N°: 23 o los residuos 89-97 de SEQ ID N°:23, donde la proteína de union comprende un marco de trabajo aceptor humano. Reivindicacion 2: La proteína de union de la reivindicacion 1, caracterizada porque la proteína de union comprende al menos 3 CDR.

公开(公告)号：AU2006252098B2

公开(公告)日：2011-02-24

申请号：AU2006252098

申请日：2006-12-18

Applicant: ABBOTT LAB

Inventor： MANKOVICH JOHN ,  GHAYUR TARIQ ,  SHORROCK CELIA ELIZABETH ,  BROCKLEHURST SIMON MARK ,  DUNCAN ALEXANDER ROBERT ,  LENNARD SIMON NICHOLAS ,  THOMPSON JULIA ELIZABETH ,  SALFELD JOCHEN ,  WHITE MICHAEL ,  LABKOVSKY BORIS ,  ROGUSKA MIKE ,  DIXON RICHARD W

IPC: C12N15/02 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/00 ,  A61P39/02 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular, antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-I8 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.